The document "Priority medical devices list for the COVID-19 response and associated technical specifications" complements this guideline.
This document provides interim guidance on the quality, performance characteristics and related standards of personal protective equipment (PPE) to be used i...n the context of COVID-19. This includes WHO Priority Medical Devices, specifically: surgical masks, non-surgical masks, gloves, googles, face shields, gowns and N95 masks. It is intended for procurement agencies, occupational health departments, infection prevention and control departments or focal points, health facility administrators, biomedical and materials engineering, PPE manufacturers and public health authorities at both national and facility levels.
more
El documento "Lista de productos sanitarios prioritarios para la respuesta a COVID-19 y especificaciones técnicas asociadas" complementa esta directriz.
Este documento proporciona una orientación provisional sobre la calidad, las características de rendimiento y las normas conexas de los equi...pos de protección personal (EPP) que se utilizarán en el contexto de COVID-19. Esto incluye los productos sanitarios prioritarios de la OMS, concretamente: mascarillas quirúrgicas, mascarillas no quirúrgicas, guantes, gafas, protectores faciales, batas y mascarillas N95. Está dirigido a los organismos de adquisición, los departamentos de salud laboral, los departamentos o puntos focales de prevención y control de infecciones, los administradores de los centros de salud, la ingeniería biomédica y de materiales, los fabricantes de EPI y las autoridades de salud pública, tanto a nivel nacional como de los centros.
more
A Situational Assessment and Five-YearAction Plan for the Africa CDC Strengthening Regional Public Health Institutions and Capacity for Surveillance and Response Program
En este documento se ofrecen orientaciones a las autoridades de salud en todos los niveles para que mejoren la tasa de éxito de la localización de contactos al asegurarse de que las actividades correspondientes se sustenten en los principios, la evidencia y las actividades de CRPC, y se suministra...n herramientas a los profesionales que participan en dicha localización a fin de asentar sus prácticas en los principios de la CRPC y mejorar igualmente su tasa de éxito.
more
The 2020 recommendations for the programmatic management of TB preventive treatment are the first to be released under the rubric of WHO consolidated TB guidelines (Module 1 – Prevention). The WHO consolidated TB guidelines will gradually group all TB recommendations and will be complemented by ma...tching modules of a consolidated operational handbook. [1] The handbook will provide practical advice on how to put in place the recommendations at the scale needed to achieve national and global impact. The first handbook module in the series will be on the programmatic management of TB preventive treatment and will accompany the 2020 guidelines.
more
The WHO operational handbook on tuberculosis: tuberculosis preventive treatment is the companion, implementation guide to the 2020 WHO guidelines on TB preventive treatment.[1] Just as these guidelines are the first to be released under the rubric of the WHO consolidated TB guidelines, this handbook... will be the first in a modular series of practical guides meant for the implementers of various aspects of the programmatic management TB.
more
26 March 2021 Slideset updated regularly to include the latest data on the evolution and duration of COVID-19 symptoms and prevalence and duration of natural immunity.
New England Journal of Medicine
April 9, 2021
DOI: 10.1056/NEJMoa2104840
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
On 9 February 2021, a first webinar entitled “Expanding our understanding of Post COVID-19 condition” was held under the auspices of WHO and in consultation with the International Severe Acute Respiratory and Emerging Infection Consortium(ISARIC), Global Research Collaboration for Infectious Dis...ease Preparedness (GloPID-R), National Institutes of Health/National Institute of Allergy and Infectious Diseases(NIH/NIAID), Long Covid SOS and patient representatives.
more
In the context of the coronavirus disease (COVID-19) pandemic response, WHO identifies young people as a priority target audience with specific concerns, experiences and behaviours. This policy brief provides relevant insights from behavioural evidence and a set of behavioural considerations for tho...se promoting COVID-19 preventive behaviours among young people. Designers of programmes and initiatives targeting youth may find it helpful to refer to the youth-specific barriers and drivers identified in this policy brief and to prioritize these for testing when planning initiatives targeted at young people.
more
This study looked at structural risk factors to COVID-19 that existed before the outbreak and may have direct and indirect effects on COVID-19 risk across all the 47 counties in Kenya. These factors are COVID-19 exposure and vulnerability and lack of adaptive capacity to COVID-19.
Pharmaceutical regulators are at the forefront of ensuring that only safe and effective medicines are authorized and available in the market. This document builds on the recommendations in the above publication and has been prepared to specifically assist national medicines regulatory authorities to... understand the nature and extent of oxytocin quality issues and to provide key technical information and quality requirements for oxytocin products in dossier assessments. Furthermore, this document also presents recommendations on other regulatory actions needed to ensure that only quality-assured oxytocin products are authorized and made available to women.
more
Prenant pour socle la vision Bénin 2025 Alafia, le Plan National de Développement 2018-2025 intègre les nouveaux enjeux de développe-ment économique et social au plan national, africain et international. Son élaboration a été un défi majeur que nous avons relevé, avec la contri-bution de t...ous les acteurs à divers niveaux : secteur public, secteur privé, institutions de la République, organisations de la société civile, parte-naires sociaux, Association Nationale des Communes du Bénin (ANCB), universitaires, Gouvernement et partenaires techniques et financiers. En unissant les efforts, le peuple béninois vient de se doter d’un outil ma-jeur de développement dont la mise en œuvre réussie offrira au Bénin l’opportunité triplement gagnante d’atteindre la Vision Bénin 2025 et de se mettre sur le sentier des Objectifs de Développement Durable (ODD) à l’horizon 2030 et de la Vision Africa 2063.
more